Keloids in rural black South Africans. Part 1: General overview and essential fatty acid hypotheses for keloid formation and prevention

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 63, Issue 5, 2000, Pages 237-245

  Louw, L ^a  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CHOLESTEROL; ESSENTIAL FATTY ACID; FATTY ACID; FREE RADICAL; PHOSPHOLIPID; TRIACYLGLYCEROL;

CLINICAL FEATURE; CONTROLLED STUDY; DIET; ERYTHROCYTE; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; HISTOPATHOLOGY; HUMAN; HYPERTROPHIC SCAR; HYPOTHESIS; KELOID; LIPID PEROXIDATION; NEGRO; NUTRITION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RURAL POPULATION; SOUTH AFRICA;

EID: 0033639261     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.2000.0207     Document Type: Article

References (114)

1. Keloids. The natural history
2. Keloids: A review
3. Keloids and hypertrophic scars
4. Hypertrophic scars and keloids. Cause and management - Current concepts
5. Keloids
6. Keloids and hypertrophic scars: A comprehensive review
7. Keloids and hypertrophic scars
8. Keloids: A review of the literature
9. On the nature of keloid and hypertrophic scars
10. Keloids
11. Hypertrophic scar and keloid
12. Keloid
13. Immunologic associations of keloids
14. Hypertrophic scars and keloids
15. Keloids and hypertrophic scars
16. Morphological and immunochemical differences between keloid and hypertrophic scar
17. The pathogenesis of hypertrophic/keloid scarring
18. Proliferating activity of dermal fibroblasts in keloids and hypertrophic scars
19. Mast cells and myofibroblasts in keloids: A light microscopic, immunohistochemical and ultrastructural study
20. Apoptosis, necrosis and proliferation: Possible implications in the aetiology of keloids
21. Hypertrophic scars and keloids: A recurrent problem revisited
22. Serum free keloid fibroblast cell culture: An in vitro model for the study of aberrant wound healing
23. Impairment in the fatty acid composition of keloids
24. Keloids: Peripheral and central differences in cell morphology and fatty acid compositions of lipids
25. The molecular basis of keloid and hypertrophic scar formation
26. Morphological and immunochemical differences between keloid and hypertrophic scars
27. Hypertrophic scars and keloids: A histologic, immunohistochemical, and ultrastructural study
28. The microvessels in hypertrophic scars, keloids and related lesions: A review
29. Ultrastructural characteristics of keloid fibroblasts
30. Contributions of electron microscopy to the study of the hypertrophic scar and related lesions
31. Apoptosis: A current molecular analysis
32. Interferons and collagen production
33. Keloids and diabetes in a family
34. Altered cytokine production in black patients with keloids
35. Fibronectin gene transcription is enhanced in abnormal wound healing
36. Hyaluronic acid metabolism in keloid fibroblasts
37. Calcium antagonists alter cell shape and induce procollagenase and synthesis in keloid and normal human dermal fibroblasts
38. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid and other fibrotic skin disorders
39. DNA binding proteins from keloid fibroblasts form unique complexes with the human fibronectin promoter
40. Inverse correlation between CD 34 expression and proline-4-hydroxylase immuno-reactivity on spindle cells noted in hypertrophic scars and keloids
41. Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy
42. Keloid fibroblasts from a Caucasian patient: Are there differences in growth kinetics?
43. Perilesional linear atrophy and hypopigmentation after intralesional corticosteroid therapy
44. Retinoic acid in the treatment of keloids
45. Silicone gel in the treatment of keloid scars
46. A controlled trial of intralesional recombinant interferon-gamma in the treatment of keloid scarring
47. Pressure therapy in treatment of hypertrophic scar, burn contracture and keloid: The Kenyan experience
48. Intralesional interferon gamma treatment for keloids and hypertrophic scars
49. Silicone gel in the treatment of keloids
50. Tissue expansion for the treatment of keloids
51. Treatment of scars and keloids with a cream containing silicone oil
52. Topical cyclosporin and T lymphocytes in keloid scars
53. In search of the optimal treatment of keloids: Report of a series and a review of the literature
54. Carbon dioxide laser for keloids
55. The effect of carbon dioxide laser surgery on the recurrence of keloids
56. Management of keloids and hypertrophic scars
57. Effects of pharmacologic agents on human keloids implanted in athymic mice: Pilot study
58. Evaluation of various methods of treating keloids and hypertrophic scars: A 10-year follow-up study
59. Hydration and occlusion treatment for hypertrophic scars and keloids
60. An approach to management of keloids
61. The inhibition of fibroblast proliferation by a novel monokine: An in vitro and in vivo study
62. Historical notes on the use of pressure in the treatment of hypertrophic scars or keloids
63. Considerations for cosmetic surgery in the black population
64. Outcomes of cryosurgery in keloids and hypertrophic scars. A prospective consecutive trial of case series
65. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts
66. Vitamin E added silicone gel sheets for treatment of hypertrophic scars and keloids
67. Management of scar contractures, hypertrophic scars and keloids
68. Keloid excision and recurrence prophylaxis via intradermal interferon-gamma injections; a pilot study
69. Failure of interferon-alpha 2b in the treatment of mature keloids
70. Laser treatment of hypertrophic scars, keloids, and striae
71. Major suppression of pro-alpha 1(I) type collagen gene expression in the dermis after keloid excision and immediate intrawound injection of triamciolone acetonide
72. Tamoxifen down-regulates TGF-beta production in keloid fibroblasts
73. In search of the optimal treatment of keloids: Report of a series and a review of the literature
74. Medical uses of essential fatty acids
75. Essential fatty acids in clinical medicine
76. Nutritional and medical importance of gamma-linoleic acid
77. Recent studies on the synthesis, beta-oxidation and deficiency of linoleate and g-linolenate: Are essential fatty acids more aptly named indispensable or conditionally dispensable fatty acids
78. Studies and perspectives of the protein kinase C family for cellular regulation
79. Fatty acid stimulation of membrane phosphatidylinositol hydrolysis by brain phosphatidylinositol phosphodiesterase
80. Arachidonic acid stimulates the formation of 1,2-diacylglycerol and phophatidic acid in human platelets
81. Differential effects of omega-3 fish oils on protein kinase activities in vitro
82. Role of fatty acids in signal transduction. Modulators and messengers
83. Fatty acids and cell signal transduction
84. Regulation of gene transcription by polyunsaturated fatty acids
85. Fatty acids: Ancestral ligands and modern co-regulators of the steroid hormone receptor cell signaling pathway
86. Role of the peroxisome proliferator-activated receptor in mediating the effects of fibrates and fatty acids on gene expression
87. Fatty acid regulation of gene expression. Its role in fuel patitioning and insulin resistance
88. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma
89. Peroxisome proliferator-activated receptors: A family of lipid-activated transcription factors
90. An update on the mechanisms of action of the peroxisome proliferator-activated (PPARs) and their roles in inflammation and cancer
91. Regulation of gene expression by dietary fat
92. Medical significance of peroxisome proliferator-activated receptors
93. Fatty acids, eicosanoids, and hypolipidemic agents regulate gene expression through direct binding to peroxisome proliferator-activated receptors
94. Differential effects of omega-3 fish oils on protein kinase activities in vitro
95. The mitogen-activated protein kinase signal transduction pathway
96. Identification of an oncoprotein- and Uv-responsive protein kinase that binds and potentiates the c-Jun activation domain
97. MAPKs: New JNK expands the group
98. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells
99. Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast
100. FADD/MORT1 is a common mediator of CD95 (FAs/APO-1) and tumor necrosis factor receptor-induced apoptosis
101. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis
102. GLUT-4, tumor necrosis factor, essential fatty acids and raf-genes and their role in insulin resistance and noninsulin dependent diabetes mellitus
103. Free radical interactions and their pathological consequences
104. Oxidative stress as a mediator for apoptosis
105. Interactions between essential fatty acids, eicosanoids, cytokines, growth factors and free radicals
106. Essential fatty acids and eicosanoids in cutaneous inflammation
107. Biological significance of arachidonic acid
108. Essential fatty acids and inflammation
109. 6, niacin and biotin; vitamin C, selenium; zinc; iron
110. Modulation of collagen synthesis by TGF-b in keloid and hypertrophic scar fibroblasts
111. Tamoxifen down-regulates TGF-b production in keloid fibroblasts
112. Tranilast, A selective inhibitor of collagen synthesis in human skin fibroblasts